PRESTIGE BIOPHARMA LIMITED

Autres langues Prestige BioPharma Limited

Actions

A950210

KR8702070002

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
8 100 ^KRW	+0,12 %		+0,87 %	-14,56 %

2023	Prestige Biopharma reçoit la désignation Fast Track de la FDA pour le PBP1510 dans le traitement du cancer du pancréas	CI
2023	Prestige BioPharma Limited met au point le premier kit de diagnostic de détection du PAUF de sa catégorie	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer	21/03/23
Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit	09/03/23
Prestige Biopharma Submits Pre-BLA Type 4 Meeting Request to FDA for Herceptin Biosimilar	14/10/22
Prestige Biologics Co., Ltd. announced that it has received KRW 6.893915 billion in funding from Prestige BioPharma Limited	05/09/22
Prestige Biologics Co., Ltd. announced that it expects to receive KRW 6.893915 billion in funding from Prestige BioPharma Limited	26/08/22
Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the Us, Europe, Canada, Mena, Brazil, Mexico, South Africa, Cis and the Sea Countries	26/07/22
US FDA Approves Prestige Biopharma’s IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510	27/06/22
Prestige Biopharma Enters MOU with Vaxine for Supply of COVID-19 Vaccine and Co-development of COVID-19/Influenza Combo Vaccine	29/03/22
The Result of the Phase 3 Study for Prestige BioPharma’s Herceptin Biosimilar, HD201(Tuznue®), Published in JAMA Oncology	11/03/22
Prestige BioPharma Limited Announces Preclinical Data of Pancreatic Cancer Treatment, PBP1510, Present in ESMO TAT 2022	08/03/22
Prestige BioPharma Limited Commences Construction of Innovative Discovery Center in Busan, Korea	19/12/21
Prestige BioPharma and Dr. Reddy’s Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast Asia	09/12/21
Prestige BioPharma Limited(KOSE:A950210) added to S&P Global BMI Index	20/09/21
Prestige BioPharma : Institutional Shareholders, Appreciate its High Growth Potential and Invest with a Long-term View	02/08/21

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Découvrez nos Contenus Gratuits pour vous Aider à Mieux Comprendre les Marchés Boursiers.

Inscription 100% Gratuite

fermer